Carcinogenesis, Teratogenesis & Mutagenesis (CTM) is the official Journal of Chinese Environmental Mutagen Society and is undertaken by Shantou University Medical College. It is the source journal for Chinese Scientific and Technical Papers and Citations. The impact factor is 0.379 and ranks fourth among more than 30 Chinese oncologic journals according to Chinese S&T Journal Citation Reports 2003.
It may be worth mentioning that the Journal has been included in 14 Chinese important indexing systems, including CSTPC, CEPS, CJFD, CMCC, CBMDISC, CAJ-CD and so on.
Editorial board of CTM deeply appreciated what you have done for us and looks forward to your further attention and contribution.

  Carcinogenesis, Teratogenesis & Mutagenesis
Honorary Editor-in-Chief:
TAN Jia-zhen
Editor-in-Chief: CHENG Shu-jun
Deputy Editor-in-Chief:
HUANG Tian-hua (Executor) LI Yong LU You-yong WU Yi-min
Director of Editorial Office: HUANG Tian-hua
Editing: Editorial Board of Carcinogenesis, Teratogenesis & Mutagenesis 22 Xinling Road, Shantou, Guangdong, China 515041,
Tel & Fax: 0754-8900267,E-mail:cemsctm@stu.edu.cn
Publishing: Science Press
Distributor: Beijing Post Office in China
Domestic: All Local Post Office in China, Code No. 80-285, Unit price ¥6.00
Overseas Distributor: China International Book Trading Corporation (P.O. Box 399, Beijing 100044, China Code No. 6364 BM), Unit price: USD & 2.00
Printing: Jingmei Color Printing Co., Ltd

 
 
 

Carcinogenesis, Teratogenesis & Mutagenesis
The forth Editorial Board

 

Yu Yingnian
 

  Dr. Yu Yingnian, pathophysiologist, graduated from Shanghai Medical University in 1954. He worked as a senior visiting scholar in Ontario Cancer Institute of Toronto University in 1989~1990. Now he is the professor of pathophysiology and supervisor of Ph.D. students in Zhejiang University School of Medicine. He was/is the member of the 3 provincial academic committees, 3 councils of international and whole China academic societies and 6 editorial boards of international and Chinese scientific journals. Since 1978, he starts his research work in the field of mechanism of mutagenesis induced by chemical carcinogens as well as the new assay technology of genotoxicity of chemicals and computer assisted structure-activity relationship analysis system (SARA) for prediction of the genotoxicity of chemicals; the molecular mechanism of non-targeted mutagenesis in mammalian cells; the kinetics of induction of CYP (cytochrome P450) gene expressions in cultured cell line, cloning and heterologous expression of cDNAs of carcinogen/drug metabolizing enzyme genes from Chinese. From 21st century on, he uses the rapid developed “-omic” technology in biologic research, i.e., the high throughput transcriptomic and proteomic techniques in the study of early response of human cells induced by representative environmental chemical pollutants (ECPs) as well as the function and expression control of relevant responsive genes/proteins. He bore responsibility for 22 National and 16 Provincial projects, and now is held responsible for a grant of National Key Basic Research and Developmental Program sponsored by National Ministry of Science and Technology; He published more than 180 refereed-papers and 13 academic books. He received 17 National and Provincial awards for his achievement in scientific research and once of Science and Technology Progress Award of Ho Leung Ho Lee Foundation as well as two honor titles from the State Council and Chinese Association of Science and Technology respectively.

 
 
 
  Cheng Shujun is currently as a professor of Cancer Institute (Hospital), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, and Chief Scientist of both China State Key Basic Research Project “Fundamental investigation of human carcinogenesis and cancer therapy and prevention” and Beijing key Cancer Research Project “Tumor biomarker profiling and human cancer diagnosis and therapy”. He worked as a visiting scientist in Laboratoire de Medicine Experimental, Institute de la Recherches Scientifiques sur le Cancer, France (1978-1981), and in Department of Pathology, Medical College of Ohio, USA (1986-1987). He has established a series of short-term tests for the detection of environmental carcinogens and anti-carcinogens in China. He was elected as a Member, Chinese Academy of Engineering in 1999. Dr. Cheng is the President of Chinese Environmental Mutagen Society, and Vice President of China Anticancer Association. He found that the tea catechins showed a significant inhibitory effect against human genital condylomas and inflammatory hyperplasia. Based on the invention, he and his collaborators had received international patents “Composition for treating condyloma acuminate” in 1998. This invention had been approved to go for clinical phase III trial by US FDA. As invited speakers, Dr. Cheng has visited many institutes at foreign countries and attended at international conferences.
 
Please use 1024×768
Copyright
© 2005 editorial office of Carcinogenesis, Teratogenesis & Mutagenesis (CTM)
Address:22 Xin-Ling Road,Shantou,Guangdong,China (515041)
Tel & Fax:0754-8900267,E-mail:cemsctm@stu.edu.cn
Support by Beijing Magtech Co.ltd